File: tg4010-14-information-publique.pdfTrial reference: A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC)Doc type: Information for the public
